Principal Investigator
Gretel Terrero
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231195
Clinical Trial Summary
NET RETREAT: A PHASE II STUDY OF 177 LUTETIUM-DOTATATE RETREATMENT VS. EVEROLIMUS OR SUNITINIB OR CABOZANTINIB IN METASTATIC/UNRESECTABLE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS
Phase
Phase II
Funding Agency/Sponsor
National Cooperative Group
Disease
Pancreatic, Liver, and Related Cancers
Contact Information
Phone Number
305-243-2647